CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled / 15 target
Drug / intervention
Rozanolixizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06720714
NCT06720714Phase 1CompletedOn Track (0.8/mo)Completion was 13mo ago
CompareCT.gov

An Open-Label, Single-Dose Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

UCB Biopharma SRL·interventional·Posted Dec 6, 2024·Updated Jun 4, 2026

In Brief

A Phase 1 clinical trial evaluating Rozanolixizumab for Healthy Participants. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedDec 6, 2024
Enrollment StartDec 3, 2024
Primary CompletionMay 12, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.6 years ago

Arms & Interventions

Rozanolixizumab armexperimental

Study participants enrolled in this arm will receive a single dose of subcutaneous rozanolixizumab

Drug: Rozanolixizumab

Interventions

Rozanolixizumabdrug

Dose formulation: Solution for injection Route of administration: Subcutaneous infusion